Trial Profile
Evaluation of efficacy in improvement of cardiac function / renal function by REZALTAS COMBINATION TABLETS on hypertension patient.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 May 2016
Price :
$35
*
At a glance
- Drugs Olmesartan medoxomil/azelnidipine (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- 28 Feb 2013 Status changed from recruiting to completed as reported by University Hospital Medical Information Network - Japan.
- 08 Mar 2011 New trial record